Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems

NCT00626236 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity
Conduct Disorder

Interventions

DRUG: SPN-810
DRUG: SPN-810
DRUG: SPN-810
DRUG: SPN-810

Sponsor

Supernus Pharmaceuticals, Inc.